Bispecific antibodies in the treatment of relapsed/refractory large B-cell lymphoma.

IF 2.9 3区医学 Q2 ONCOLOGY Expert Review of Anticancer Therapy Pub Date : 2024-08-01 Epub Date: 2024-06-03 DOI:10.1080/14737140.2024.2362186

Gulrayz Ahmed, Fateeha Furqan, Elham Nasrollahi, Mehdi Hamadani

{"title":"Bispecific antibodies in the treatment of relapsed/refractory large B-cell lymphoma.","authors":"Gulrayz Ahmed, Fateeha Furqan, Elham Nasrollahi, Mehdi Hamadani","doi":"10.1080/14737140.2024.2362186","DOIUrl":null,"url":null,"abstract":"Introduction: The management of relapsed and/or refractory (R/R) large B-cell lymphoma (LBCL) has witnessed dramatic changes in the recent past. Despite the availability of multiple novel immunotherapies in R/R setting, there remains an unmet need for off-the-shelf therapies, particularly in patients with primary refractory, multiply relapsed disease or those experiencing cellular immunotherapy failure. To harness the power of the T-cell mediated immunity, a novel class of drugs called bispecific antibodies (BsAbs) have been developed. These BsAbs are currently under investigation both in frontline and R/R setting and hold the potential to revolutionize the management of LBCL.Areas covered: This review article summarizes the currently available BsAbs, their mode of action, efficacy, and safety data for untreated and R/R LBCL. In addition, the role of these BsAbs in combination with currently available chemoimmunotherapy regimens is also discussed.Expert opinion: Two BsAbs have secured FDA approval for R/R LBCL, with expected approval of more BsAbs (including in earlier treatment lines). These drugs provide a highly efficacious and relatively safe treatment option for patients with highly pretreated disease including relapse after cellular immunotherapies. In addition, these BsAbs provide a platform for chemotherapy-free regimen for older/frail patients.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":null,"pages":null},"PeriodicalIF":2.9000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anticancer Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737140.2024.2362186","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/3 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: The management of relapsed and/or refractory (R/R) large B-cell lymphoma (LBCL) has witnessed dramatic changes in the recent past. Despite the availability of multiple novel immunotherapies in R/R setting, there remains an unmet need for off-the-shelf therapies, particularly in patients with primary refractory, multiply relapsed disease or those experiencing cellular immunotherapy failure. To harness the power of the T-cell mediated immunity, a novel class of drugs called bispecific antibodies (BsAbs) have been developed. These BsAbs are currently under investigation both in frontline and R/R setting and hold the potential to revolutionize the management of LBCL.

Areas covered: This review article summarizes the currently available BsAbs, their mode of action, efficacy, and safety data for untreated and R/R LBCL. In addition, the role of these BsAbs in combination with currently available chemoimmunotherapy regimens is also discussed.

Expert opinion: Two BsAbs have secured FDA approval for R/R LBCL, with expected approval of more BsAbs (including in earlier treatment lines). These drugs provide a highly efficacious and relatively safe treatment option for patients with highly pretreated disease including relapse after cellular immunotherapies. In addition, these BsAbs provide a platform for chemotherapy-free regimen for older/frail patients.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

治疗复发性/难治性大 B 细胞淋巴瘤的双特异性抗体。

导言：近年来，复发和/或难治性（R/R）大B细胞淋巴瘤（LBCL）的治疗发生了巨大变化。尽管有多种新型免疫疗法可用于复发/难治性淋巴瘤治疗，但对现成疗法的需求仍未得到满足，尤其是对初治难治、多次复发或细胞免疫疗法失败的患者。为了利用 T 细胞介导的免疫力，一种名为双特异性抗体（BsAbs）的新型药物应运而生。这些双特异性抗体目前正在一线治疗和R/R治疗中进行研究，有望彻底改变LBCL的治疗方法：这篇综述文章总结了目前可用的 BsAbs、其作用模式、疗效以及用于未经治疗和 R/R LBCL 的安全性数据。此外，文章还讨论了这些双特异性抗体与目前可用的化疗免疫疗法方案联合使用的作用：两种双特异性抗体已获得 FDA 批准用于治疗 R/R LBCL，预计还会有更多的双特异性抗体获得批准（包括早期治疗方案）。这些药物为高度预处理疾病（包括细胞免疫疗法后复发）患者提供了一种高效且相对安全的治疗选择。此外，这些 BsAbs 还为老年/体弱患者的无化疗方案提供了一个平台。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Expert Review of Anticancer Therapy 医学-肿瘤学

CiteScore

5.10

自引率

3.00%

发文量

100

审稿时长

4-8 weeks

期刊介绍： Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches. Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care. Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections: Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.